Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 101-110 of 639 results
British Journal of Anaesthesia, 2023 • November 24, 2022
This study examined the effect of intrathecal injection of NIS-lncRNA antisense oligonucleotides on neuropathic pain caused by chronic constriction injury (CCI) of the sciatic nerve, spinal nerve liga...
KEY FINDING: Intrathecal NIS-lncRNA antisense oligonucleotides attenuated CCI-induced mechanical allodynia, heat hyperalgesia, cold hyperalgesia, and ongoing nociceptive responses, without changing basal or acute nociceptive responses and locomotor function.
Ann Transl Med, 2022 • November 1, 2022
This study investigated the potential of Astragaloside IV (AS-IV) to alleviate spinal cord injury (SCI) by controlling ferroptosis in H2O2-damaged PC12 cells in vitro. The results indicated that AS-IV...
KEY FINDING: AS-IV treatment (1.0 μM for 48 h) significantly increased the viability of PC12 cells and enhanced their proliferation.
Bioactive Materials, 2023 • January 1, 2023
This study introduces a novel drug delivery system using peptide CAQK-modified, siRNA-loaded EVs (C-EVs-siRNA) for targeted therapy of spinal cord injury (SCI). The C-EVs-siRNA specifically targeted t...
KEY FINDING: The study demonstrates that CAQK-modified, siRNA-loaded EVs (C-EVs-siRNA) can specifically deliver siRNA to the SCI region and be taken up by target cells.
Frontiers in Neurology, 2022 • November 29, 2022
This systematic review examined existing literature on the efficacy of 4-aminopyridine (4-AP) as a treatment for spinal cord injury (SCI). The remaining seven studies provided evidence that in various r...
KEY FINDING: The review confirms the efficacy of 4-AP in improving several conditions resulting from SCI.
Journal of Orthopaedic Surgery and Research, 2022 • December 5, 2022
This study investigates the potential of Astragaloside IV (AS IV) to treat intervertebral disc degeneration (IDD) by alleviating inflammation, apoptosis, and extracellular matrix (ECM) degeneration in...
KEY FINDING: AS IV effectively alleviated IL-1β-induced inflammation, apoptosis, and extracellular matrix degeneration in NPCs.
Biomedicines, 2022 • December 12, 2022
The review explores the stable gastric pentadecapeptide BPC 157's effects on striated, smooth, and heart muscles, highlighting its healing potential for myotendinous junction injuries. BPC 157 therapy...
KEY FINDING: BPC 157 therapy shows potential in healing severed myotendinous junctions, combining healing of transected and detached tendons, muscles, ligaments, and bones.
Cells, 2022 • December 14, 2022
The study demonstrates that cutaneous injection of resiniferatoxin (RTX) can completely alleviate and prevent nerve-injury-induced neuropathic pain in rats. RTX treatment resulted in the downregulatio...
KEY FINDING: Intraplantar injection of RTX completely reversed the development of chronic thermal and mechanical hypersensitivity in rats with nerve injury.
Cells, 2022 • December 19, 2022
The study investigated the expression and distribution of 2-AG in the brain and spinal cord of a spare nerve injury (SNI) mice model of neuropathic pain using DESI-MSI. The results showed that 2-AG ex...
KEY FINDING: On days 3 and 7 after SNI treatment, 2-AG expression decreased in the hypothalamus, midbrain, and especially in the periaqueductal gray (PAG) region.
Life, 2022 • November 23, 2022
Spinal cord injury (SCI) remains a significant cause of disability, with oxidative stress, inflammation, apoptosis, and autophagy playing crucial roles in its pathogenesis. Increased inflammation, oxi...
KEY FINDING: Quercetin and its derivatives have shown potential in promoting neuronal cell regeneration in SCI by attenuating several dysregulated pathways.
Heliyon, 2022 • December 2, 2022
This study investigated the effects of Wuzi Yanzong Pill (WYP) on Cuprizone (CPZ)-induced demyelination in mice, focusing on the central nervous system (CNS) microenvironment. The results showed that ...
KEY FINDING: WYP improved mood abnormalities and reduced demyelination in CPZ-treated mice.